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Summary
Objective Currently available studies that fully analyse the met-
abolic parameters in patients with prolactinoma are scarce and
discordant. The aim of this study was to evaluate the metabolic
effects of cabergoline (CAB) treatment in patients with newly
diagnosed prolactinoma in relation to disease control and CAB
dosage.
Design This is a retrospective clinical-based therapy analysis.
Patients Forty-three patients with prolactinoma (eight men, 35
women), aged 3365  1123 years, were evaluated metabolically
at baseline and after 12 months of CAB treatment.
Measurements Body mass index (BMI), systolic and diastolic
blood pressure, waist circumference (WC), lipid profile, haemo-
globinA1c (HbA1c), glucose and insulin levels (and their areas
under the curve, AUC) after an oral glucose tolerance test,
homoeostasis model assessment of insulin resistance (Homa-IR)
index, insulin sensitivity index (ISI) Matsuda, oral disposition
index (DIo) and visceral adiposity index (VAI) were measured
at baseline and after 12 months of treatment.
Results Twelve months of CAB reduced WC (P < 0001), total
(P = 0001) and low-density lipoprotein \terol (P < 0001),
triglycerides (P = 0024), fasting insulin (P < 0001), AUCINSULIN
(P < 0001), HbA1c (P = 0022), Homa-IR (P < 0001) and VAI
(P < 0001), with a concomitant increase in high-density lipo-
protein cholesterol (P < 0001) and in ISI Matsuda (P < 0001),
regardless of the degree of reduction in prolactin levels. The
patients receiving higher doses (>050 mg/week) of CAB showed
lower BMI (P = 0009), fasting insulin (P = 0001), Homa-IR
(P < 0001) and VAI (P = 0018) and higher ISI Matsuda
(P = 0002) and DIo (P = 0011), compared with those on lower
doses.
Conclusions A significant metabolic improvement was
observed in patients with prolactinoma after 12 months of CAB
treatment, especially when higher doses were used, highlighting
the importance of considering the metabolic profile in these
patients and the role of active treatment with high CAB doses.
(Received 14 January 2013; returned for revision 30 January 2013;
finally revised 27 February 2013; accepted 14 March 2013)
Introduction
Prolactinoma is the most frequent secreting pituitary tumour
and mainly affects the female gender.1 Besides the well-known
consequences on the reproductive axis both in men and women,
hyperprolactinaemia can be associated with alterations in body
composition and obesity,2 although the evidence is discordant.
Reduced bone density 3,4 and total body fat 5,6 have been posi-
tively associated with high prolactin (PRL) levels in patients with
prolactinoma. Schmid et al.7 demonstrated significantly higher
body mass index (BMI) in patients with macroprolactinoma
than both patients with inactive adenomas and the general pop-
ulation. Conversely, Naliato et al. showed similar body fat in
women with prolactinoma and controls.5
Dopamine agonists (DA) are recognized as the recommended
therapy to lower PRL levels and decrease tumour size for
patients with prolactinoma, and the use of cabergoline (CAB) is
suggested in preference to other DA because of its higher effi-
cacy.8 Several studies have analysed the effects of DA treatment
on body fat and metabolism, but most of them used mainly
bromocriptine.9 In this setting, reduced body fat content and a
lower risk of metabolic syndrome have been associated with the
normalization of PRL during DA treatment.5 Decreased BMI
and waist circumference (WC) have been reported during DA
therapy in some studies,10 but not in others.11 However,
currently available studies that fully analyse the metabolic
parameters in patients with prolactinoma at diagnosis and
during treatment with CAB are scarce, and discordant data have
been reported. Based on the data that link the body composition
parameters with PRL levels and DA administration, the aim of
the current study was to fully evaluate the effects of 12 months
of CAB treatment on the metabolic syndrome (MS), insulin
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sensitivity and visceral adiposity index (VAI),12 a surrogate
parameter indicating adipose tissue dysfunction associated with
cardiometabolic risk, in a group of patients with newly diagnosed
prolactinoma in relation to disease control and CAB dosage.
Patients and methods
We conducted a retrospective chart review of patients affected
by hyperprolactinaemia seen at the Unit of Endocrinology of the
University of Palermo from 1 January 2011 to 30 October 2012.
We analysed data from a total of 89 patients. The flow chart of
patient distribution and inclusion in the study according to the
criteria adopted is shown in Fig. 1.
Patients with hyperprolactinaemia secondary to drugs (includ-
ing neuroleptics, antidepressants, opiates and gastrointestinal
prokinetics) or mixed-secreting tumours, those already receiving
dopamine agonists at the baseline visit and those with a follow-
up of less than 12 months were excluded from this analysis. In
addition, we excluded patients with multiple pituitary hormone
deficiencies and/or the presence of other concomitant causes of
overt hypogonadism to avoid the potential impact of hormonal
deficit or gonadal replacement therapy on metabolic parameters.
No women receiving oestrogens and/or progesterone as contra-
ceptives or postmenopausal hormone replacement therapy were
included. All patients with already known glucose abnormalities
were treated with diet alone. Patients already receiving hypogly-
caemic agents were excluded from this study. For the purpose of
this study, we enrolled 43 consecutive patients (8 men, 19%; 35
women, 81%) aged 3365  1123 years (range: 16–63), with
newly diagnosed prolactinoma. The diagnosis was based on signs
and symptoms of hyperprolactinaemia, high-serum PRL levels
and magnetic resonance imaging (MRI) demonstrating a pitui-
tary tumour.8 This study was conducted in compliance with the
‘Ethical principles for medical research involving human
subjects’ of the Helsinki Declaration. At the time of hospitalization,
all patients signed a consent form for the scientific use of their
data and the identity of the participants remained anonymous
during the analysis.
Study design
All patients, at baseline and after 12 months of CAB treatment,
underwent a complete clinical and metabolic evaluation. Prolac-
tin levels were considered as the mean value of measurements in
at least three blood samples collected at 20-min intervals for
1 h, obtained through venous cannulation, without repeated
venepuncture stress. Women who presented with menstrual
cycles, even if irregular, were studied in the early follicular phase
(1–7 days from bleeding). In all patients, MRI revealed the
presence of a pituitary tumour. Tumour volume was calculated
in line with the Di Chiro and Nelson formula (vol-
ume = height 9 length 9 width 9 p/6) and was expressed as
mm3. BMI and systolic (SBP) and diastolic (DBP) blood pres-
sure were measured in all patients. WC was measured at the
midpoint between the lower rib and the iliac crest. After an
overnight fast, total, high-density lipoprotein (HDL) and
Fig. 1 Flow chart of patient distribution and
inclusion in the study according to criteria adopted
and dosage of cabergoline used. Dopamine
agonists: dopamine agonists; EP: oestro/
progesterone; HA: hypoglycaemic agents; CAB:
cabergoline; PRL: prolactin.
© 2013 John Wiley & Sons Ltd
Clinical Endocrinology (2013), 0, 1–8
2 A. Ciresi et al.
low-density lipoprotein (LDL) cholesterol, triglycerides and hae-
moglobinA1c (HbA1c) were measured. In addition, an oral glu-
cose tolerance test (OGTT) was performed by measuring plasma
blood glucose and insulin levels every 30 min for 2 h after a
75-g oral glucose load. The areas under the curve of glucose
(AUCGLU) and insulin (AUCINS) during the 2-h OGTT were
also calculated. The diagnosis of diabetes or glucose tolerance
abnormalities was made according to the American Association
of Clinical Endocrinologists medical guidelines.13 Basal insulin
resistance (IR) was assessed using homoeostasis model assess-
ment of the insulin resistance (Homa-IR) index.14 Stimulated
insulin sensitivity was measured using the insulin sensitivity
index (ISI), a composite index derived from the OGTT and vali-
dated by Matsuda et al.15 Total insulin secretion was assessed by
AUCINS, while b-cell function relative to insulin sensitivity was
assessed by oral disposition index (DIo).16
VAI was calculated as described,12 using the following formula
differentiated according to sex, when TG is triglyceride level
expressed in mM and HDL is HDL cholesterol level expressed in
mM:
Men:VAI¼½WC=3968þð188BMIÞðTG=103Þð131=HDLÞ
Women:VAI¼½WC=3658þð189BMIÞðTG=081Þð152=HDLÞ
After the diagnosis was made, all patients received CAB at the
initial weekly dose of 050 mg for the first 6 months. After this
period, the CAB dose was adjusted to maintain serum PRL levels
within the normal range for sex or was increased to the maximal
tolerable dose for patients who did not achieve normal PRL lev-
els or did not show significant tumour shrinkage. We considered
disease control to be attained when PRL levels decreased to nor-
mal values for healthy subjects, according to gender (Fig. 1).
The mean weekly dose used during the study period was
058  030 mg (range: 025–180).
Hormone and biochemical assays
Glucose and lipid (HDL, LDL and total cholesterol, triglyce-
rides) levels were measured in our centralized laboratory by
standard methods. Serum insulin was measured by ELISA (DRG
Instruments GmbH, Germany). The sensitivity of the methods
was 1 mIU/l. The normal insulin range (mIU/l) was 5–19. The
conversion factor from conventional to SI units was 6945. Dur-
ing the entire study period, serum PRL was measured by chemi-
luminescent assay (Immulite 2000; Diagnostic Products, Los
Angeles, CA) with a sensitivity of 32 mU/l. The intra- and
interassay coefficients of variation were 23 and 59%, respec-
tively. Normal ranges were 38–500 and 40–354 mU/l for women
and men, respectively.
Statistical analysis
The Statistical Packages for Social Sciences SPSS version 17 were
used for data analysis. All quantitative variables showed normal
distribution (normality of distribution was assessed by the Kol-
mogorov–Smirnov test). Baseline and after-treatment variables
were presented as mean  Standard Deviation (SD) for continu-
ous variables; rates and proportions were calculated for categori-
cal data. Differences between groups in univariate analysis were
detected by the unpaired Student’s t-test for continuous vari-
ables and by the chi-square test and Fisher’s exact test (when
appropriate) for categorical variables. The differences between
paired continuous variables (before and after 12 months of ther-
apy) were analysed by the paired Student’s t-test for continuous
variables and by the McNemar test for categorical variables. A P
value of <005 was considered statistically significant.
Results
Baseline
The hormonal and metabolic parameters of patients at diagnosis
are shown in Table 1. The mean PRL levels at diagnosis were
3715  5718 mU/l with a mean tumour volume of
Table 1. Hormonal and metabolic parameters before and after
12 months of treatment with cabergoline
Patients with prolactinoma
(No. 43)
P
Basal 12 months
Mean  SD Mean  SD
Tumour volume (mm3) 1056  519 816  358 <0001
Prolactin (mU/l) 3715  5718 529  712 0001
No. (%) No. (%)
Normal glucose tolerance (NGT) 27 (628) 39 (907) 0004
Impaired fasting glucose (IFG) 5 (116) 1 (23) 0218
Impaired glucose tolerance (IGT) 10 (233) 3 (7) 0039
Diabetes mellitus (DM) 1 (23) – 1
Metabolic syndrome 13 (302) 6 (14) 0016
Mean  SD Mean  SD
BMI (kg/m2) 2557  518 2541  497 0177
WC (cm) 8881  1048 8713  1015 <0001
Total cholesterol (mM) 470  098 430  073 0001
HDL cholesterol (mM) 119  021 128  021 <0001
LDL cholesterol (mM) 285  093 242  068 <0001
Triglycerides (mM) 143  065 130  050 0024
Fasting glucose (mM) 518  081 533  099 0337
Fasting Insulin (pM) 11798  4689 8642  2590 <0001
HbA1c (%) 536  062 518  043 0022
Homa-IR 387  153 293  096 <0001
Matsuda Index 320  128 475  144 <0001
AUC2hGlucose
(mM;120 min)
860  167 840  161 0357
AUC2hInsulin
(pM;120 min)
58963  21286 37739  11249 <0001
DIo 172  153 2  221 0404
Visceral adiposity
index (VAI)
236  132 194  101 <0001
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1056  519 mm3. The mean BMI and WC values were
2557  518 and 8881  1048, respectively. Using the
National Cholesterol Education Program (NCEP-Adult Treat-
ment Panel III, ATP III) criteria,17 MS was found in 13 patients
(302%). Twenty-seven of 43 patients (628%) were classified as
having normal glucose tolerance (NGT), 5 (116%) impaired
fasting glucose (IFG), 10 (233%) impaired glucose tolerance
(IGT) and only 1 patient had newly diagnosed overt diabetes
mellitus (DM), according to the American Association of Clini-
cal Endocrinologists medical guidelines.13 No correlation
between PRL levels and BMI, CV, VAI and other metabolic
parameters at diagnosis was found (data not shown).
At 12 months of treatment
The hormonal and metabolic parameters of patients after CAB
treatment are shown in Table 1. As expected, at 12 months of
treatment, a significant decrease in PRL levels (5292  712 vs
3715  5718 mU/l; P = 0001) and tumour volume
(816  358 vs 1056  519 mm3; P < 0001) was found. As a
whole, 24 of 43 patients (558%) were classified as controlled
and 19 of 43 (442%) as uncontrolled.
We found a significant increase in the prevalence of NGT
(907 vs 628%; P = 0004) with a concomitant decrease in cases
of IGT (7 vs 233%; P = 0039) and a trend to reduction in the
cases of IFG, although not statistically significant (23 vs 116%;
P = 0218). The single case of DM diagnosed at baseline was not
confirmed after 12 months of treatment. MS was detected in 6
(14%) patients versus 13 patients (302%) before treatment
(P = 0016). A significant decrease in WC (8713  1015 vs
8881  1048 cm; P < 0001), without a significant decrease in
BMI (2541  497 vs 2557  518 kg/m2; P = 0177), was also
found.
As regards the lipid profile, we found a significant decrease in
total cholesterol (430  073 vs 470  098 mM; P = 0001),
LDL cholesterol (242  068 vs 285  093 mM; P < 0001)
and triglycerides (130  050 vs 143  065 mM; P = 0024),
with a concomitant significant increase in HDL cholesterol
(128  021 vs 119  021 mM; P < 0001).
As regards glucose metabolism, a significant reduction in fast-
ing insulin (8642  2590 vs 11798  4689 pM; P < 0001),
AUCINS (37739  11249 vs 58963  21286; P < 0001), HbA1c
(518  043 vs 536  062%; P = 0022) and Homa-IR
(293  096 vs 387  153; P < 0001) with a significant
increase in ISI Matsuda (475  144 vs 320  128; P < 0001)
was detected (Fig. 2a). VAI was significantly decreased
(194  101 vs 236  132¸P < 0001) after 12 months of
treatment (Fig. 2d). No significant difference was found in fast-
ing glucose (P = 0337), AUCGLU (P = 0357) and DIo
(P = 0404) (Fig. 2g). No correlation between PRL and BMI,
CV, VAI and other metabolic parameters was found at
12 months of treatment (data not shown).
When we analysed the hormonal and metabolic parameters in
patients grouped according to achievement of disease control,
the two groups only differed in PRL levels (P < 0001) and
tumour volume (P = 0016) (Table 2, Fig. 2b,e,h).
Grouping the patients according to median weekly dose of
CAB used during the 12-month-follow-up [050 (037–075)
mg], those treated with a low dose (LD:  50th centile; i.e. 
050 mg) were 29 (674%) and those with a high dose (HD:
>50th centile; i.e. >050 mg) were 14 (326%). No difference was
found in tumour volume (P = 0625) or PRL levels (P = 0430)
between the two groups. MS was found in 1 patient (72%)
receiving HD of CAB and in 5 patients (172%) on LD
(P = 0645). NGT, IFG and IGT were found in 26 (896%) and
13 (928%), 0 and 1 (72%), 3 (104%) and 0 patients receiving
HD and LD, respectively, without significant differences between
the two patient groups. The data of patients grouped according
to CAB dose are shown in Table 3. The patients receiving HD
showed lower BMI (2312  271 vs 2651  545 Kg/m2;
P = 0009), fasting insulin (6920  1767 vs 9473  2533;
P = 0001), Homa-IR (221  064 vs 328  090; P < 0001)
and VAI (131  044 vs 207  111; P = 0018) (Fig. 2f) com-
pared with those receiving LD, with concomitant higher ISI
Matsuda (570  128 vs 429  129; P = 0002) (Fig. 2c) and
DIo (320  352 vs. 141  074; P = 0011).(Fig. 2i). No dif-
ference in the other metabolic parameters was found between
the two groups of patients.
Discussion
The role of PRL as a metabolic hormone and the metabolic
effect of DA treatment in patients with prolactinoma are not
fully understood. Our data demonstrate that 12 months of CAB
treatment improves most of the metabolic parameters and the
degree of glucose tolerance, mainly when higher doses of CAB
are used.
In this study, a control group was not recruited as our aim
was to evaluate the metabolic parameters during DA treatment,
and for this purpose, we used patients as their own controls.
Weight gain and impaired lipid profile have frequently been
associated with hyperprolactinaemia, and a link between ele-
vated PRL levels and glucose abnormalities or hyperinsulina-
emia has been well documented.18–21 The mechanisms of these
associations are still poorly understood. The involvement of
PRL in pancreatic b-cell and insulin production and secretion
has been proposed,22,23 and a role of PRL in reducing lipopro-
tein lipase activity in adipose tissue with consequent increase
in triglycerides has been demonstrated.24 An involvement of
adipokines in prolactinoma has also been suggested. It is well
known that leptin plays a major role in food intake and body
energy balance,25 and Balci et al. recently demonstrated strong
immunoreactivity for leptin protein in prolactinomas, assuming
a cosecretion of PRL and leptin.26 These observations could
partially explain some metabolic features observed in patients
with prolactinoma, such as the presence of insulin resistance,
although to date discordant data are available. Indeed, no cor-
relation between PRL and leptin levels nor a decrease in leptin
during DA treatment has been observed.11 Hypogonadism,
which is frequently associated with hyperprolactinaemia, has
been considered an additional possible mechanism involved in
weight gain in these patients.27 For this reason, to avoid any
© 2013 John Wiley & Sons Ltd
Clinical Endocrinology (2013), 0, 1–8
4 A. Ciresi et al.
interference, we decided to exclude from this analysis patients
with overt hypogonadism associated with prolactinoma.
Recently, waist/hip ratio, lipid profile, Homa-IR and adiponec-
tin levels were found significantly altered in 20 patients with
prolactinoma with uncontrolled PRL levels compared with
healthy subjects,28 and Tuzcu et al.29 demonstrated a state of
insulin resistance in 16 patients with hyperprolactinaemia using
a euglycaemic hyperinsulinaemic clamp. However, the reduced
degree of insulin sensitivity described in patients with elevated
PRL seems not to have any association with BMI or waist cir-
cumference.30 Our results are in line with these findings.
Indeed, in our patients, no association between PRL levels and
metabolic parameters was found either at baseline or after
12 months of treatment with CAB, and no difference in meta-
bolic profile was found between patients with uncontrolled and
controlled PRL levels during treatment. In this light, PRL
seems not to be directly involved in the metabolic features of
patients with prolactinoma. The absence of significant differ-
ences in metabolic parameters between patients with persistent
high PRL levels and patients with controlled disease strengthens
this hypothesis.
Dopamine has been shown to play a role in increased energy
expenditure and downregulated food intake.31 The reduction in
dopaminergic tone associated with hyperprolactinaemia has been
considered as an additional possible mechanism involved in
weight gain in patients with prolactinoma, and the lower body fat
content in patients that normalizes the PRL levels is likely due to
dopamine receptor type 2 (DR2) activation as a result of DA
treatment.5 In this connection, it has been suggested that the DR2
gene may play a role in the regulation of weight.32 A role of DA
in glucose and lipid metabolism has been well documented both
in diabetic and obese subjects,33,34 but most of the available data
are under bromocriptine treatment.35,36 For these reasons, we
aimed to evaluate the CAB effect on metabolic parameters. Most
of the available studies have focused on metabolic parameters
such as weight or BMI, highlighting the prevalence of obesity in
patients with prolactinoma,7 and the reduction in weight after the
normalization of PRL levels during DA treatment 2,37 although
with discordant results.29,38 In our cohort of patients with hyper-
prolactinaemia, while WC significantly decreased after treatment,
BMI did not change significantly, suggesting the presence of other
factors influencing the improvement in metabolic parameters.
(a) (b) (c)
(d) (e) (f)
(g) (h) (i)
Fig. 2 Representation of insulin sensitivity index Matsuda, visceral adiposity index and oral disposition index (DIo) in patients with prolactinoma
before and after cabergoline treatment (left), grouped according to control of the disease (in the middle) and according to cabergoline dosage used
(right). CAB: cabergoline; LD: low dose; HD: high dose.
© 2013 John Wiley & Sons Ltd
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The available studies on the effect of DA on lipid metabolism are
not fully consistent.38,39 We found a significant improvement in
lipid profile, as demonstrated by the increase in HDL cholesterol
and the decrease in LDL cholesterol and triglycerides, in line with
the data of Berinder et al.10
The mechanisms by which DA could improve glucose metabo-
lism may include suppression of endogenous glucose production
or increased splanchnic glucose uptake after glucose ingestion.36
A tendency to an improvement in insulin sensitivity, assessed by
both ISI Matsuda and clamp, was reported after DA treatment.9,10
These findings are concordant with our results. Indeed, we
observed a significant improvement in glucose tolerance and
prevalence of MS, with a decrease in insulin levels, an improve-
ment in insulin sensitivity indices and a concomitant reduction
in HbA1c. The improvement of the sole case of DM after
12 months of treatment, without glucose lowering treatment, is
in line with previous data.10 Our data demonstrated that the rela-
tionship between the decrease in PRL levels and the improvement
in insulin sensitivity and the other metabolic parameters seems to
reflect the effect of CAB treatment, rather than the association
between PRL and BMI. Because our patients did not show signifi-
cant changes in BMI, other mechanisms seem to be involved in
the beneficial effects of DA treatment on metabolic profile. In this
light, the role of VAI cannot be ruled out. VAI is a sex-specific
mathematical index based on anthropometric and metabolic
parameters and could be considered a surrogate marker of adi-
pose tissue function and distribution. This index has been dem-
onstrated to be independently correlated with insulin sensitivity
and cardiometabolic risk in the general population,12 in women
with polycystic ovary syndrome40 and in newly diagnosed
patients with acromegaly, where VAI significantly correlates with
adipocytokine levels.41 After CAB treatment, our patients had sig-
nificantly reduced VAI. Therefore, an improvement in adipose
tissue function could be considered to have a major role in the
change in metabolic profile after treatment. In this light, in line
with previous studies, the improvement in insulin sensitivity after
DA treatment could be considered to be linked to the decrease in
PRL levels, to the improvement of body composition, as
Table 2. Hormonal and metabolic parameters of patients grouped
according to control of disease after 12 months of treatment with
cabergoline
Controlled
patients
(No. 24)
Uncontrolled
patients (No. 19)
PMean  SD Mean  SD
Tumor volume (mm3) 695  239 975  429 0016
Prolactin (mU/l) 143  110 996  781 <0001
No. (%) No. (%)
Normal glucose tolerance (NGT) 21 (875) 18 (947) 0618
Impaired fasting glucose (IFG) 1 (41) – 1
Impaired glucose tolerance (IGT) 2 (83) 1 (52) 1
Diabetes mellitus (DM) – – –
Metabolic syndrome 4 (166) 2 (105) 0678
Mean  SD Mean  SD
BMI (kg/m2) 2506  542 2586  443 0596
WC (cm) 8725  925 87  1145 0939
Total cholesterol (mM) 422  074 440  072 0450
HDL cholesterol (mM) 126  021 130  021 0510
LDL cholesterol (mM) 234  073 251  063 0412
Triglycerides (mM) 134  055 125  043 0537
Fasting glucose (mM) 530  057 536  136 0869
Fasting Insulin (pM) 8594  2324 8703  2958 0896
HbA1c (%) 515  043 522  043 0597
Homa-IR 293  093 292  102 0982
Matsuda Index 473  131 477  162 0936
AUC2hGlucose (mM;120 min) 821  120 862  204 0444
AUC2hInsulin (pM;120 min) 36561  7811 39227  14599 0447
Oral Disposition Index (DIo) 179  192 225  257 0521
Visceral adiposity index (VAI) 205  117 153  066 0096
Table 3. Hormonal and metabolic parameters of patients grouped
according to cabergoline dosage after 12 months of treatment
Patients under
high-dose
cabergoline
(No. 14)
Patients under low-
dose cabergoline
(No. 29)
PMean  SD Mean  SD
Tumour volume (mm3) 866  477 792  294 0625
Prolactin (mU/l) 683  965 449  544 0430
No. (%) No. (%)
Normal glucose tolerance
(NGT)
13 (928) 26 (896) 1
Impaired fasting glucose (IFG) 1 (72) – 0326
Impaired glucose tolerance
(IGT)
– 3 (104) 0539
Diabetes mellitus (DM) – – –
Metabolic syndrome 1 (72) 5 (172) 0645
Mean  SD Mean  SD
BMI (kg/m2) 2312  271 2651  545 0009
WC (cm) 8414  710 8858  1116 0182
Total cholesterol (mM) 445  062 423  078 0321
HDL cholesterol (mM) 133  026 125  018 0324
LDL cholesterol (mM) 257  058 234  072 0282
Triglycerides (mM) 118  042 136  053 0243
Fasting glucose (mM) 499  061 549  110 0067
Fasting insulin (pM) 6920  1767 9473  2533 0001
HbA1c (%) 501  038 526  043 0070
Homa-IR 221  064 328  090 <0001
Matsuda Index 570  128 429  129 0002
AUC2hGlucose (mM;120 min) 790  105 864  179 0099
AUC2hInsulin (pM;120 min) 34354  9431 39373  11834 0143
Oral Disposition Index
(DIo)
320  352 141  074 0011
Visceral adiposity index
(VAI)
131  044 207  111 0018
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demonstrated by the reduction in WC and VAI, to DA treatment
or to a combination of these factors. In this connection, our data
show that patients treated with HD of CAB had a more marked
improvement in metabolic profile, highlighted by BMI, insulin,
Homa-IR, ISI Matsuda and VAI values, than patients treated with
LD. In addition, the first group of patients showed higher DIo,
demonstrating a more efficient and adequate insulin secretion
relative to insulin sensitivity.
In conclusion, a significant metabolic improvement is
observed in patients with prolactinoma after 12 months of CAB
treatment and the reason for this is probably multifactorial. Our
data highlight the importance of considering the metabolic pro-
file in these patients and the role of active treatment with high
CAB doses which, besides normalizing hormonal levels, also
improve metabolic parameters and insulin sensitivity indices.
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